Loading clinical trials...
Loading clinical trials...
A Phase 0 Master Protocol Using the CIVO® Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients With Solid Tumors
Conditions
Interventions
Rilvegostomig
Volrustomig
+2 more
Locations
12
United States
UC Davis
Sacramento, California, United States
Emory Winship Cancer Institute
Atlanta, Georgia, United States
LSU Health Sciences Center - Shreveport
Shreveport, Louisiana, United States
Montefiore Medical Center
The Bronx, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Start Date
July 26, 2021
Primary Completion Date
December 1, 2031
Completion Date
December 1, 2031
Last Updated
April 18, 2024
NCT05720117
NCT06898450
NCT06658951
NCT06625775
NCT05098132
NCT05101070
Lead Sponsor
Presage Biosciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions